Pharmaceutical Product Supply – TRIMETHOPRIM AND POLYMYXIN B SULFATES OP

The contract entails the manufacture and supply of 5,000 units of a specified ophthalmic antibiotic formulation containing trimethoprim and polymyxin B sulfates, produced in full compliance with FDA current Good Manufacturing Practices. All production activities must meet stringent quality and regulatory standards to ensure safety and efficacy for ophthalmic use. The contractor is responsible for complete packaging and labeling in accordance with both FDA regulations and specific Department of Defense requirements, ensuring traceability, proper identification, and readiness for military medical use. Delivery of the finished product is mandated to fulfill Department of Defense logistics needs, with all units to be shipped to designated military or government locations under strict timelines and handling protocols. The contract is classified as a subcontract under NAICS code 325412, awarded through the Defense Logistics Agency, and reflects a procurement initiated to support the readiness of military healthcare systems. The solicitation was posted in July 2026 and is linked to a specific contract vehicle managed under DLA’s procurement system, indicating this is part of a larger, ongoing supply chain effort for essential pharmaceuticals within the defense infrastructure.